Figures & data
Figure 1. Structure of the decision tree from first diagnostic imaging to confirmed treatment decision. MDCT, three-phase multi-detector computed tomography; ECCM-MRI, extracellular contrast media-enhanced magnetic resonance imaging; Gd-EOB-DTPA-MRI, gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid magnetic resonance imaging; HCC, hepatocellular carcinoma; TACE, transcatheter arterial chemoembolization.
Table 1. Input probabilities for number and tumor size at first imaging.
Table 2. Input probabilities for confirmation of HCC at first imaging in Thailand and Korea.
Table 3. Costs for diagnostic procedures and treatment options in Korea and Thailand from the hospital perspective.Table Footnotea
Figure 2. Need for further confirmation of a single tumor in (a) Korea and (b) Thailand and four or more tumors in (c) Korea and (d) Thailand. ECCM-MRI, extracellular contrast media-enhanced magnetic resonance imaging; Gd-EOB-DTPA-MRI, gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid magnetic resonance imaging; MDCT, three-phase multi-detector computed tomography.
Table 4. Reduction in intra-surgical treatment modification (mean across all tumor numbers and size categories).
Table 5. Total costs per patient from the payer’s and hospital’s perspective.
Figure 3. Total cost savings of using Gd-EOB-DTPA-MRI as the first imaging procedure compared with MDCT or ECCM-MRI in (a) Korea and (b) Thailand. ECCM-MRI, extracellular contrast media-enhanced magnetic resonance imaging; Gd-EOB-DTPA-MRI, gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid magnetic resonance imaging; MDCT, three-phase multi-detector computed tomography.
Table 6. Upper limit of cost of imaging with Gd-EOB-DTPA where it is cost neutral Gd-EOB-DTPA-MRI compared with the other two imaging modalities (USD).
Table 7. Impact of TACE cost on overall per patient cost.
Table 8. Impact of personnel cost impact on overall per patient cost, hospital perspective.